Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations

Cancer Research

Volumn 58, Issue 11, 1998, Pages 2385-2396

  Egorin, Merrill J ^a,d   Rosen, D Marc ^a   Wolff, Jordan H ^a   Callery, Patrick S ^c   Musser, Steven M ^b   Eiseman, Julie L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; CARBON MONOXIDE; CYCLOHEXANE OXIDE; CYTOCHROME P450; EPOXIDE; EPOXIDE HYDROLASE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; KETOCONAZOLE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; LIVER; MASS SPECTROMETRY; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032101569     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Schnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., DiOrio, C. I., Barbacci, E. G., Miller, P. E., Pollack, V. A., Savage, D. M., Sloan, D. E., Pustilnik, L, R., Moyer, J. D., and Moyer, M. P. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J. Med. Chem., 38: 3813-3820, 1995.
2. erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem., 38: 3806-3812, 1995.
3. McIlwrath, A. J., Brunton, V. G., and Brown, R. Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemother. Pharmacol., 37: 423-428, 1996.
4. erbB2, and Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother. Pharmacol., 40: 60-64, 1997.
5. Miller, P., DiOrio, C., Moyer, M., Schnur, R. C., Bruskin, A., Cullen, W., and Moyer, J. D. Depletion of the erbB-2 gene product p 185 by benzoquinoid ansamycins. Cancer Res., 54: 2724-2730, 1994.
6. Blagosklonny, M. V., Toretsky, J., and Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11: 933-939, 1995.
7. erbB2 binds to GRP94 in vivo. J. Biol. Chem., 271: 4974-4977, 1996.
8. Miller, P., Schnur, R. C., Barbacci, E., Moyer, M. P., and Moyer, J. D. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem. Biophys. Res. Commun., 201: 1313-1319, 1994.
9. v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994
10. Page, J., Heath, J., Fulton, R., Yalkowsky, E., Tabibi, E., Tomaszewski, J., Smith, A., and Rodman, L. Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) loxicity in rats. Proc. Am. Assoc. Cancer Res., 38: 308, 1997.
11. Eiseman, J. L., Sentz, D. L., Zuhowski, E. G., Ramsland, T. S., Rosen, D. M., Reyna, S. P., and Egorin, M. J. Plasma pharmacokinetics and tissue distribution of 17-allallylaminogeldanamycin (NSC 330507), a prodrug for geldanamycin, in CD2F1 mice and Fisher 344 rats. Proc. Am. Assoc. Cancer Res., 38: 308, 1997.
12. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
13. Jamis-Dow, C. A., Klecker, R. W., Katki, A. G., and Collins, J. M. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother. Pharmacol., 36: 107-114, 1995.
14. Skoda, R. C., Demierre, A., McBride, O. W., Gonzalez, F. J., and Meyer, U. A. Human microsomal xenobiotic epoxide hydrolase, complementary DNA sequence, complementary DNA-directed expression in COS-1 cells, and chromosomal localization. J. Biol. Chem., 263: 1549-1554, 1988.
15. Davies, R. L., Crespi, C. L., Rudo, K., Turner, T. R., and Langenbach, R. Development of a human cell line by selection and drug-metabolizing gene transfection with increased capacity to activate promutagens. Carcinogenesis (Lond.), 10: 885-891, 1989.
16. Bogaards, J. J. P., Venekamp, J. C., and van Bladeren, P. J. The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes. Chemico-Biol. Interact., 102: 169-182, 1996.
17. Li, A. P, Kaminski, D. L., and Rasmussen, A. Substrates of human hepatic cytochrome P450 3A4. Toxicology, 104: 1-8, 1995.
18. Labroo, R. B., Thummel, K. E., Kunze, K. L., Podoo, T., Trager, W. F., and Karasch, E. D. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab. Dispos., 232: 490-496, 1995.
19. Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J. C., and Beaune, P. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol., 33: 1883-1895, 1994.
20. Yun, C. H., Okerholm, R. A., and Guengerich, P. Oxidation of the antihistamine drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealdulation and C-hydroxylation. Drug Metab. Dispos., 21: 403-409, 1993.
21. Shou, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V., and Korzekwa, K. R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 33: 6450-6455, 1994.
22. Fitzsimmons, M. E., and Collins, J. M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab. Dispos., 25: 256-266, 1997.
23. Seidergard, J., and DePierre, J. W. Microsomal epoxide hydrolase properties, regulation, and function. Biochim. Biophys. Acta, 695: 251-270, 1983.
24. Lu, A. Y. H., and Miwa, G. T. Molecular properties and biological functions of microsomal epoxide hydrolase. Annu. Rev. Toxicol., 20: 513-531, 1980.
25. Yang, S. K., McCourt, D. W., Leutz, J. C., and Gelboin, H. V. Benzo(a)pyrene diol epoxides: mechanism of enzymatic formation and optically active intermediates. Science (Washington DC), 196: 1199-1201, 1977.
26. Wood, A. W., Wislocki, P. G., Chang, R. L., Levin, W., Lu, A. Y. H., Yagi, H., Hernandez, O., Jerina, D. M., and Conney, A. H. Mutagenicity and cytotoxicity of benzo(a)pyrene benzo-ring epoxides. Cancer Res., 36: 3358-3366, 1976.
27. erbB2 binds to GRP94 in vivo. J. Biol. Chem., 271: 4974-4977, 1996.
28. Schulte, T. W., Blagosklonny, M. V., Ingui, C., and Neckers, L. Disruption of the Raf-1-hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem., 270: 24585-24588, 1995.
29. Philips, F. S., Sternberg, S. S., Cronin, A. P., and Vidal, P. Cyclophosphamide and urinary bladder toxicity. Cancer Res., 21: 1577-1589, 1961.
30. DeFronzo, R. A., Abeloff, M., Braine, H., Humphrey, R. L., and Davis, P. J. Renal dysfunction after treatment with isophosphamide (NSC-109724). Cancer Chemother. Rep., 58 (Part 1): 375-382, 1974.
31. Cox, P. J. Cyclophosphamide cystitis: identification of acrolein as the causative agent. Biochem. Pharmacol., 28: 2045-2049, 1979.
32. Scheef, W., Klein, H. O., and Brock, N. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat. Rep., 63: 501-501, 1979.
33. Andriole, G. L., Sandlund, J. T., Miser, J. M., Arasi, V., Linehan, M., and Magrath, I. T. The efficacy of Mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J. Clin. Oncol., 5: 799-803, 1987.